Skip to main content

BMY

Stock
Health Care
Drug Manufacturers - General

Performance overview

BMY Price
Price Chart

Forward-looking statistics

Beta
0.35
Risk
28.89%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees34K
Market cap$84.1B

Fundamentals

Enterprise value$133.8B
Revenue$47.6B
Revenue per employee—
Profit margin11.38%
Debt to equity293.85

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$2.68
Dividend per share$2.48
Revenue per share$23.48
Avg trading volume (30 day)$604M
Avg trading volume (10 day)$741M
Put-call ratio—

Macro factor sensitivity

Growth+0.3
Credit+3.0
Liquidity+0.7
Inflation-2.6
Commodities-0.7
Interest Rates-0.9

Valuation

Dividend yield5.29%
PEG Ratio6.67
Price to sales2.00
P/E Ratio6.67
Enterprise Value to Revenue2.81
Price to book5.49

Upcoming events

Next earnings dayFebruary 5, 2026
Next dividend day—
Ex. dividend dayJuly 3, 2025

News

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research (July 18, 2025)
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.

CNBC (July 17, 2025)
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb & Co. BMY is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga (July 14, 2025)
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

Zacks Investment Research (July 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free